{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:15:14Z","timestamp":1782720914725,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"IUCT Transla","award":["Cluster"],"award-info":[{"award-number":["Cluster"]}]},{"name":"IUCT Transla","award":["Cluster"],"award-info":[{"award-number":["Cluster"]}]},{"name":"IUCT Transla","award":["Cluster"],"award-info":[{"award-number":["Cluster"]}]},{"name":"IUCT Transla","award":["Cluster"],"award-info":[{"award-number":["Cluster"]}]},{"name":"IUCT Transla","award":["Cluster"],"award-info":[{"award-number":["Cluster"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01653-y","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:49:49Z","timestamp":1744116589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Morphometric analysis of neoplastic cell clusters in high-grade serous ovarian cancer ascites identifies a promising prognostic factor: a retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Beno\u00eet","family":"Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Rigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"White-Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bataillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Guillermet-Guibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Basset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"3","key":"1653_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Mai. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin Mai"},{"issue":"10177","key":"1653_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet Lond Engl 23 Mars. 2019;393(10177):1240\u201353.","journal-title":"Lancet Lond Engl 23 Mars"},{"issue":"1","key":"1653_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, K\u00f6bel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 1 Janv. 2019;111(1):60\u20138.","journal-title":"J Natl Cancer Inst 1 Janv"},{"issue":"5","key":"1653_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4149\/neo_2013_071","volume":"60","author":"H Huang","year":"2013","unstructured":"Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, et al. Clinical significance of Ascites in epithelial ovarian cancer. Neoplasma. 2013;60(5):546\u201352.","journal-title":"Neoplasma"},{"issue":"1","key":"1653_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1525-1438.2006.00777.x","volume":"17","author":"A Ayhan","year":"2007","unstructured":"Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2007;17(1):68\u201375.","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"issue":"7","key":"1653_CR6","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol - Cell Physiol 1 Oct. 2015;309(7):C444\u201356.","journal-title":"Am J Physiol - Cell Physiol 1 Oct"},{"issue":"11","key":"1653_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 1 Nov. 2006;7(11):925\u201334.","journal-title":"Lancet Oncol 1 Nov"},{"issue":"25","key":"1653_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian cancer. N Engl J Med 19 D\u00e9c. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med 19 D\u00e9c"},{"key":"1653_CR9","doi-asserted-by":"crossref","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 29 d\u00e9c. 2011;365(26):2473\u201383.","DOI":"10.1056\/NEJMoa1104390"},{"issue":"10","key":"1653_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 1 Oct. 2012;23(10):2605\u201312.","journal-title":"Ann Oncol 1 Oct"},{"issue":"17","key":"1653_CR11","first-page":"2260","volume":"283","author":"J Boyd","year":"2000","unstructured":"Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 3 Mai. 2000;283(17):2260\u20135.","journal-title":"JAMA 3 Mai"},{"key":"1653_CR12","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.ctrv.2021.102294","volume":"100","author":"B You","year":"2021","unstructured":"You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, et al. The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treat Rev Nov. 2021;100:102294.","journal-title":"Cancer Treat Rev Nov"},{"issue":"43","key":"1653_CR13","doi-asserted-by":"publisher","first-page":"27220","DOI":"10.18632\/oncotarget.25513","volume":"9","author":"A Le Naour","year":"2018","unstructured":"Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, et al. Effect of combined Inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance. Oncotarget 5 Juin. 2018;9(43):27220\u201332.","journal-title":"Oncotarget 5 Juin"},{"issue":"1","key":"1653_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41467-017-02289-3","volume":"8","author":"M Schelker","year":"2017","unstructured":"Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat Commun 11 D\u00e9c. 2017;8(1):2032.","journal-title":"Nat Commun 11 D\u00e9c"},{"issue":"1","key":"1653_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/gutjnl-2019-319748","volume":"70","author":"JA Ajani","year":"2021","unstructured":"Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 Inhibition. Gut Janv. 2021;70(1):55\u201366.","journal-title":"Gut Janv"},{"issue":"4","key":"1653_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, Liu C. Elevated VEGF concentrations in Ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013;73(4):309\u201314.","journal-title":"Scand J Clin Lab Invest"},{"key":"1653_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2018.03.019","volume":"482","author":"V Dalal","year":"2018","unstructured":"Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, et al. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin Chim Acta Int J Clin Chem Juill. 2018;482:27\u201332.","journal-title":"Clin Chim Acta Int J Clin Chem Juill"},{"issue":"6","key":"1653_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jasc.2020.05.015","volume":"9","author":"D Pinto","year":"2020","unstructured":"Pinto D, Chandra A, Crothers BA, Kurtycz DFI, Schmitt F. The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management. J Am Soc Cytopathol. 2020;9(6):469\u201377.","journal-title":"J Am Soc Cytopathol"},{"issue":"12","key":"1653_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/dc.23569","volume":"44","author":"JJ Schulte","year":"2016","unstructured":"Schulte JJ, Lastra RR. Abdominopelvic washings in gynecologic pathology: A comprehensive review. Diagn Cytopathol D\u00e9c. 2016;44(12):1039\u201357.","journal-title":"Diagn Cytopathol D\u00e9c"},{"issue":"1","key":"1653_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/dc.2840020104","volume":"2","author":"M Kashimura","year":"1986","unstructured":"Kashimura M, Matsukuma K, Kamura T, Matsuyama T, Tsukamoto N. Cytologic findings in peritoneal fluids from patients with ovarian serous adenocarcinoma. Diagn Cytopathol. 1986;2(1):13\u20136.","journal-title":"Diagn Cytopathol"},{"key":"1653_CR21","doi-asserted-by":"crossref","unstructured":"Roque R, Costa Sousa F, Figueiredo-Dias M. Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination. Oncol Rev. 29 mai. 2020;14(2):475.","DOI":"10.4081\/oncol.2020.475"},{"issue":"4","key":"1653_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1158\/1541-7786.MCR-13-0489","volume":"12","author":"A Usui","year":"2014","unstructured":"Usui A, Ko SY, Barengo N, Naora H. P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions. Mol Cancer Res MCR Avr. 2014;12(4):504\u201313.","journal-title":"Mol Cancer Res MCR Avr"},{"key":"1653_CR23","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1038\/srep05646","volume":"4","author":"S Xu","year":"2014","unstructured":"Xu S, Yang Y, Dong L, Qiu W, Yang L, Wang X, et al. Construction and characteristics of an E-cadherin-related three-dimensional suspension growth model of ovarian cancer. Sci Rep 10 Juill. 2014;4:5646.","journal-title":"Sci Rep 10 Juill"},{"issue":"22","key":"1653_CR24","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-Ovarian High-Grade serous carcinoma. J Clin Oncol 1 Ao\u00fbt. 2015;33(22):2457\u201363.","journal-title":"J Clin Oncol 1 Ao\u00fbt"},{"issue":"2","key":"1653_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","volume":"154","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Powell A, B\u00f6hm S, Gilks CB, Stewart CJR, Meniawy TM, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol Ao\u00fbt. 2019;154(2):441\u20138.","journal-title":"Gynecol Oncol Ao\u00fbt"},{"issue":"5","key":"1653_CR26","first-page":"1169","volume":"32","author":"Y Negi","year":"2018","unstructured":"Negi Y, Kuribayashi K, Funaguchi N, Doi H, Mikami K, Minami T, et al. Early-stage clinical characterization of malignant pleural mesothelioma. Vivo Athens Greece. 2018;32(5):1169\u201374.","journal-title":"Vivo Athens Greece"},{"key":"1653_CR27","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.3389\/fimmu.2018.03156","volume":"9","author":"C Wefers","year":"2018","unstructured":"Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger LFAG, et al. Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in Ascites. Front Immunol. 2018;9:3156.","journal-title":"Front Immunol"},{"issue":"1","key":"1653_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1476-4598-9-7","volume":"9","author":"X Zhang","year":"2010","unstructured":"Zhang X, Xu L, hua, Yu Q. Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth. Mol Cancer 14 Janv. 2010;9(1):7.","journal-title":"Mol Cancer 14 Janv"},{"issue":"8","key":"1653_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10585-016-9821-y","volume":"33","author":"I Matte","year":"2016","unstructured":"Matte I, Legault CM, Garde-Granger P, Laplante C, Bessette P, Rancourt C, et al. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin Exp Metastasis D\u00e9c. 2016;33(8):839\u201352.","journal-title":"Clin Exp Metastasis D\u00e9c"},{"key":"1653_CR30","doi-asserted-by":"crossref","unstructured":"Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y et al. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res CR. 23 juin. 2021;40(1):207.","DOI":"10.1186\/s13046-021-02003-8"},{"issue":"6","key":"1653_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/1541-7786.MCR-17-0593","volume":"16","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Montminy T, Azad T, Lightbody E, Hao Y, SenGupta S, et al. PI3K positively regulates YAP and TAZ in mammary tumorigenesis through multiple signaling pathways. Mol Cancer Res MCR Juin. 2018;16(6):1046\u201358.","journal-title":"Mol Cancer Res MCR Juin"},{"issue":"11","key":"1653_CR32","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tibs.2021.05.005","volume":"46","author":"M Di-Luoffo","year":"2021","unstructured":"Di-Luoffo M, Ben-Meriem Z, Lefebvre P, Delarue M, Guillermet-Guibert J. PI3K functions as a hub in mechanotransduction. Trends Biochem Sci Nov. 2021;46(11):878\u201388.","journal-title":"Trends Biochem Sci Nov"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01653-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:18:33Z","timestamp":1744219113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01653-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"74"}}